The discovery of robust antidepressant actions exerted by the N-methyl-D-aspartate receptor
(NMDAR) antagonist (R, S)-ketamine has been a crucial breakthrough in mood disorder …

Major Depressive Disorder (MDD) is a leading cause of disability worldwide, creating a high
medical and socioeconomic burden. There is a growing interest in the biological …

Although the efficacy of racemate ketamine, a rapid onset and sustained antidepressant, for
patients with treatment-resistant depression was a serendipitous finding, clinical use of …

Depression is the most prevalent and among the most debilitating of psychiatric disorders.
The precise neurobiology of this illness is unknown. Several lines of evidence suggest that …

Background The N-methyl-D-aspartate glutamate receptor antagonist ketamine, delivered
via an intravenous route, has shown rapid antidepressant effects in patients with treatment …

Major depressive disorder (MDD) is a heterogeneous disease affecting one out of five
individuals and is the leading cause of disability worldwide. Presently, MDD is considered a …

Cannabidiol (CBD), the main non-psychotomimetic component of marihuana, exhibits
anxiolytic-like properties in many behavioural tests, although its potential for treating major …

Context The pathogenesis of depression is not fully understood, but studies suggest that low-
grade systemic inflammation contributes to the development of depression. Objective To test …

Exposure to stressful events can be differently perceived by individuals and can have
persistent sequelae depending on the level of stress resilience or vulnerability of each …

Increased rostral anterior cingulate cortex (rACC) activity has emerged as a promising
predictor of treatment response in depression, but neither the reliability of this relationship …